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Abstract
Objectives Perifissural nodules (PFNs) are a common finding
on chest CT, and are thought to represent non-malignant le-
sions. However, data outside a lung cancer-screening setting
are currently lacking.
Methods In a nested case-control design, out of a total cohort
of 16,850 patients ≥ 40 years of age who underwent routine
chest CT (2004-2012), 186 eligible subjects with incident
lung cancer and 511 controls without were investigated. All
non-calcified nodules ≥ 4 mm were semi-automatically anno-
tated. Lung cancer location and subject characteristics were
recorded.
Results Cases (56 %male) had a median age of 64 years (IQR
59–70). Controls (60 %male) were slightly younger (p<0.01),
median age of 61 years (IQR 51–70). A total of 262/1,278 (21
%) unique non-calcified nodules represented a PFN. None of
these were traced to a lung malignancy over a median follow-
up of around 4.5 years. PFNs were most often located in the
lower lung zones (72 %, p<0.001). Median diameter was
4.6 mm (range: 4.0–8.1), volume 51 mm3 (range: 32–278).
Some showed growth rates < 400 days.
Conclusions Our data show that incidental PFNs do not rep-
resent lung cancer in a routine care, heterogeneous population.
This confirms prior screening-based results.
Key Points
• One-fifth of non-calcified nodules represented a perifissural
nodule in our non-screening population.
• PFNs fairly often show larger size, and can show interval
growth.
•When morphologically resembling a PFN, nodules are near-
ly certainly not a malignancy.
• The assumed benign aetiology of PFNs seems valid outside
the screening setting.
Keywords Computed tomography . Adult . Solitary
pulmonary nodule . Lung neoplasms . Guideline
Abbreviations
CT Computed tomography
PFN Perifissural nodule
VDT Volume doubling time
Introduction
Solid pulmonary nodules are a common finding in computed
tomography (CT) of the chest, and management decisions
regarding these nodules are encountered by many on an al-
most daily basis. The majority of solid nodules, however, will
not represent a malignancy. Therefore, it is of utmost impor-
tance to reliably differentiate (potentially) malignant nodules
from benign lesions. To guide this process, screening focused
guidelines like Lung-RADS (Lung Screening Reporting and
Data System) are available [1]. Additionally, for clinical use
ACCP (American College of Chest Physicians) [2],
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Fleischner Society [3] and British Thoracic Society [4] guide-
lines have been issued.
A substantial subset of solid pulmonary nodules will rep-
resent perifissural nodules (PFNs), most likely representing
intrapulmonary lymph nodes. Morphologically these are sol-
id, homogeneous nodules with a smooth margin, and are oval
or rounded, lentiform or triangular in shape [5–7]. It has been
proposed to differentiate between typical and atypical PFNs
on the one hand and non-PFN nodules on the other, based on
the presence of fissural attachment and morphological charac-
teristics [5]. Prior lung cancer-screening studies have shown
that solid pulmonary nodules that conform to the definition of
PFNs – either typical or atypical – do not represent or develop
into lung malignancies over time, and should be regarded as
non-suspect and benign lesions [5, 8].
Outside a screening setting, these perifissural nodules are
also regularly found in daily routine imaging, and one may
assume that they behave similarly. However, data on PFNs in
routine chest imaging are currently lacking. Therefore, the
purpose of our study was to assess the presence and behaviour
of PFNs in a routine care, non-screening and heterogeneous
population.
Materials and methods
This retrospective study was reviewed by the institutional re-
view board, who waived the need for informed consent.
Subjects
This study is an ancillary project of a larger incident lung
cancer study in non-screening subjects. For that study we ret-
rospectively collected all subjects > 40 years of age who re-
ceived a CT of the chest in our academic hospital between
2004 and 2012 (N=16,850). No selection was made based
on imaging indication or in-/outpatient status. All eligible sub-
jects were linked to the Dutch National Cancer Registry to
identify those who did and did not develop lung cancer after
the CT examination, until the end of 2014 (N=1,095 lung
cancer cases). As we were interested in incident lung cancers,
we excluded 867 subjects with a lung cancer diagnosis before
or within 2 months after the CT (N=228 incident lung cancer
cases). Applying a nested case-control design (ratio 1:3), we
included these 228 subjects with a lung malignancy diagnosis
(‘cases’), together with a randomly selected sample of 684 out
of all subjects that did not develop a lung malignancy (‘con-
trols’). We collected all available chest CT imaging up to 2
months before index date in cases, and the single oldest CT
scan in controls. Lung cancer location and date of diagnosis
were available from the National Cancer Registry. Patient
characteristics and clinical information were obtained from
the hospital radiology system.
CT scanning
Scans were obtained at different scanners of the same vendor
(Philips Healthcare, Best, The Netherlands). Since imaging
was performed for various clinical indications, different scan
protocols were applied. All scans were obtained with
standard-dose protocols (90–140 kV at a median of 239
mAs). The vast majority of scans were reconstructed with
thin-slice collimation (≤ 1 mm; 99 %), with a maximum slice
thickness of 3 mm. Generally a sharp reconstruction filter was
used (Philips-C; > 80 %).
Nodule annotation
One of the authors, a radiology resident with a PhD in chest
imaging and 7 years of experience in thoracic radiology, visu-
ally assessed all chest CT scans. Exclusion criteria were: in-
sufficient image quality defined as mechanical ventilation,
substantial consolidation or collapse, as well as severe
motion/breathing artefacts that impeded reliable interpretation
of lung tissue.
In the eligible CT scans all non-calcified nodules ≥ 4 mm
were semi-automatically annotated by the observer using a
dedicated nodule software workstation (CIRRUS Lung
Screening, Diagnostic Image Analysis Group, Nijmegen,
The Netherlands; Fraunhofer MEVIS, Bremen, Germany).
Scans were read in a single session in which the software
automatically provided suggestions for pulmonary nodules
by placing a marker/box. The observer was able to accept,
decline or adjust these. Additionally, the examination was
thoroughly read for any additional nodules that were not pick-
ed up by the Cirrus software. The workstation enables image
viewing in different window/level-settings, and provides re-
constructions in all three orthogonal planes. Nodule type, vol-
ume, effective diameter, as well as location were scored for
each annotated pulmonary nodule. In case of solid nodules a
distinction was made between PFNs and non-PFN nodules,
based on whether it morphologically showed a (peri)fissural
or juxtapleural location (within 15 mm of the pleura), an oval
or triangular shape, and smooth borders [5, 6]. Figure 1 shows
two examples of a PFN, a group that by definition comprised
both typical and atypical PFNs. Solid nodules that did not
conform to the abovementioned definition of a PFN were
regarded as non-PFN solid intrapulmonary nodules.
Besides the nodule characteristics, additional features were
scored to evaluate potential interrelations. Emphysema was
visually assessed. Adapted from Lynch et al. [9] – in which
the authors describe the different types and extent of pulmo-
nary emphysema – we assigned an overall score of emphyse-
ma extent on a four-point scale (none, mild, moderate and
severe) [10]. Bronchial wall thickening was subjectively de-
fined as thicker airway walls than normal, as there is no strict
definition [10]. It was scored dichotomously as present or
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absent. Vascular calcifications in the coronaries and thoracic
aorta were scored on a four-point scale (none, mild, moderate
and severe), based on a previously described method [11].
Last, hilar or mediastinal lymphadenopathy was scored as
present or absent, defined as nodes with a short-axis over 10
mm. To evaluate generalizability of visual scoring, a test sam-
ple of 34 scans (5 %) was also scored by two other authors
(with over 10 and 20 years of experience, respectively).
Statistical analysis
Straightforward descriptive statistics were used for this study.
Age was compared between groups using Mann-Whitney U
testing. Proportions were compared using chi-squared testing.
Interobserver variability was calculated using Cohen’s kappa
in dichotomous data, and using linear weighted kappa in or-
dinal data. Unless indicated otherwise, values given are me-
dians with interquartile range (IQR). A p-value < 0.05 was
considered statistically significant.
Results
Subjects
After retrieval and visual assessment of the CT images, a total
of 186 cases and 511 controls remained. This was due to
exclusion of in total 42/228 cases and 173/684 controls, main-
ly due to insufficient image quality or slice-thickness. Figure 2
provides the flowchart of our study population selection.
Cases were 56 % male, with a median age at the time of
imaging of 64 years (IQR 59–70). Controls were 60 % male,
and slightly younger at a median age of 61 years (IQR 51–70).
Table 1 summarises basic study population characteristics.
Pulmonary nodules
A total of 1,278 unique non-calcified nodules were found; 599
nodules in 178 cases (8/186 cases showed no nodules on
available CT imaging) , and 679 nodules in 288 controls
(223/511 controls showed no nodules on available CT imag-
ing). In total 262 unique PFNs were annotated in 179 subjects
(i.e. 69 unique PFNs in 43 cases, and 193 unique PFNs in 136
controls). Thus, one in every five nodules represented a PFN
(21 %; 262/1278).
Location, size and growth of perifissural nodules (PFNs)
PFNs were most often located in the lower lobes, i.e. in 72 %
(189/262), p<0.001. Figure 3 shows the distribution of PFNs
throughout the lungs. The median diameter of all PFNs was
4.6 mm (range: 4.0–8.1, modus: 4.1), while volume median
was 51 mm3 (range: 32–278, modus: 33). Volume doubling
time (VDT) could be determined in a subset of 28 PFNs in 22
patients who were imaged multiple times during an interval of
424 days (IQR 187–585). Between the consecutive scans, two
out of six growing PFNs showed a growth rate with a VDTof
400–600 days, while four showed a VDT of ≤ 400 days.
Figure 4 shows an example of PFN growth. Three PFNs with
more than one scan interval showed that none grew continu-
ously, with volume decrease or stable volume in the other
intervals. When using the Lung-RADS definition of growth
(> 1.5 mm increase in diameter), only a single PFN fulfilled
the criteria. This nodule decreased in size in another scan
interval.
For those individuals with at least one PFN, the time inter-
val between CT imaging and linkage with the cancer registry
had a median of 53 months (IQR 30–85, range 6–126). None
of the nodules annotated as PFN developed into or could be
traced to a registered lung malignancy.
Fig. 1 Example of two perifissural nodules (PFNs), morphologically
presenting as a typical and an atypical PFN. Left panel: 70-year-old
male, sagittal image. Triangular nodule in the left lower lobe attached to
a fissure, meeting the definition of a typical PFN. Right panel: 69-year-
old male, sagittal image. Fissure-attached nodule in the right middle lobe
that is convex on one side and rounded on the other, meeting the defini-
tion of an atypical PFN
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Correlation with other chest CT parameters and patient
characteristics
Interobserver agreement was moderate to substantial for the
visual scoring (κ-values: 0.51–0.74). We found no significant
difference in the presence or extent of emphysema, bronchial
wall thickening, vascular calcifications or hilar/mediastinal
lymphadenopathy between those with and without PFNs.
PFN presence was also not different between those with or
without any known extra-pulmonary malignancy, nor was
there a relationship with age. However, there was a slight male
preponderance (29 % vs. 22 %, p=0.04). When looking into
the number of PFNs per subject it was found that those with
hilar/mediastinal lymphadenopathy more often showed mul-
tiplicity (p<0.001 for > 2 PFNs).
Discussion
Our study describes the presence and behavior of PFNs in a
routine, non-screening population. Our results show that inci-
dental PFNs on routine care chest imaging do not represent
lung cancer, underlining prior results in lung cancer-screening
participants.
Fig. 2 Flow chart of study population selection
Table 1 Study population
characteristics Cases with incident
lung cancers (N=186)
Controls without lung cancer
during follow-up (N=511)
p value
Sex, N (%)
Male
Female
104 (56)
82 (44)
305 (60)
206 (40)
NS
Age, median (IQR) 64 (59–70) 61 (51–70) <0.01
PFN, N (%)
Present
Absent
43 (23)
143 (77)
136 (27)
375 (73)
NS
Prior extrapulmonary
malignancy, N (%)
Present
Absent
59 (32)
127 (68)
260 (51)
251 (49)
0.001
IQR interquartile range, PFN perifissural nodule.
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PFNs are regularly encountered in daily practice, in a pop-
ulation that differs significantly from lung cancer-screening
cohorts. It was previously reported that none of the PFNs that
were evaluated in screening populations turned out to be ma-
lignant after several years of follow-up [5, 8]. It has since been
assumed that this result could be extrapolated to clinical
subjects, as shown by the incorporation into current nodule
management guidelines for clinical use [3, 4]. However, to our
knowledge this has never been tested. In the present study, out
of the 262 evaluated PFNs, none were traced to a lung malig-
nancy in follow-up. Although a single-centre study, our results
support that PFNs are not lung cancer, a claim that is indeed
valid in a broader spectrum of subjects. Our data therefore
further strengthen the idea that when a lung nodule is encoun-
tered that morphologically conforms to a PFN, it is safe not to
induce follow-up.
Currently, the ACCP guidelines [2] and the screening-
focused Lung-RADS [1] do not separately discuss PFNs,
and thus classify them as small solid pulmonary nodules at
risk for lung cancer. Therefore, a PFNwill induce unnecessary
follow-up similar to a non-PFN nodule of the same size. The
new Fleischner document and British Thoracic Society (BTS)
guidelines do distinguish PFNs as a separate and non-
malignant entity [3, 4]. However, the Fleischner document
does not apply in subjects with a prior malignancy [3], patients
which BTS does include, although based on low-level evi-
dence. Depending on the practice, subjects with a prior malig-
nancy can make up a substantial percentage of all subjects that
receive CT imaging. Since our study also included subjects
with prior malignancies, our data add significantly to the
available literature by showing that in this subpopulation too
PFNs do not represent lung cancer. It has to be emphasised,
however, that our study is unable to indicate whether or not a
Fig. 4 Example of growth in a perifissural nodule (PFN). A well-
circumscribed, homogeneous, triangular-shaped solid nodule along the
major fissure in the right lower lobe, presenting a PFN in an 58-year-
old female without a prior malignancy. Nodule volume in the six
consecutive CT scans ranged between 50 and 81 mm3 (diameter: 4.6–
5.4) with a volume doubling time (VDT) of 361 days between CT2 and
CT3, while a decrease with a VDT of -118 was seen between CT4 and
CT5, as shown in the panels above
Fig. 3 Location of perifissural nodules (PFNs) throughout the lungs
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PFN can contain a metastasis, since our outcome data only
provided information on whether a patient developed a prima-
ry lung malignancy or not. Future research should elucidate
this through prospective long-term follow-up of PFNs in pa-
tients with specific malignancies.
In the present study, we also looked into PFN size and
growth. Most of the evaluated PFNs are rather small with a
median of 4.6 mm and 51 mm3. It has to be noted that even
this is an overestimation, given that we used a lower threshold
of 4 mm in this study. Nevertheless, about a quarter of the PFNs
were 80 mm3 or larger and about a third were 5 mm or larger,
which are for example the cut-off values used for follow-up of
solid nodules in the BTS guidelines [4]. Thus, it is not uncom-
mon to encounter somewhat larger PFNs, and this should not be
a reason to reject the diagnosis and suspect a lung cancer.
Although longitudinal imaging was available in only a
small subset of cases, we found growth in some PFNs, some-
times even at a substantial growth rate. This is in line with
previous screening-based literature [5, 8]. Growth is suppos-
edly related to the fact that PFNs most likely represent
intrapulmonary lymph nodes [3, 5], which may show reactive
changes. While any growing lesion should raise concern and
warrant closer inspection, our study underlines that PFN
growth does not increase the likelihood of lung cancer, not
even if the growth rate falls within the range generally accept-
ed to indicate malignant growth [12]. Widespread knowledge
on possible growth of PFNs might prevent unnecessary
follow-up and additional imaging techniques, with associated
costs and (radiation) burden. However, further evaluation of
growth in clinically detected PFNs should be performed in
future studies.
Another characteristic that we could reproduce in our non-
screening study population is that PFNs are more often found
in the lower part of the lungs [6, 8, 13]. This in contrast to an
upper lobe locationmore often seen in lungmalignancies [14].
Nevertheless, upper versus lower lobe location does not reli-
ably differentiate between a benign or malignant nature of a
nodule. This also applies for the (peri)fissural or juxtapleural
location [3, 5, 15]. It is therefore important to emphasise that
nodule morphology remains the only parameter for
distinguishing benign PFNs from possibly malignant lesions.
Regarding nodule presence, we found that there was no
relation to other chest CT biomarkers or age. In our cohort a
slight male preponderence was found, a finding not reported
in a previous screening-based study [8]. We cannot explain
this finding with certainty, but believe that gender does not
influence PFN characterisation. Given that PFNs are overall
seen equally in cases and controls, in subjects with or without
prior malignancies, and that there is no association with bron-
chitis, emphysema, vascular calcifications or mediastinal
lymphadenopathy, it is likely a rather randomly occurring en-
tity without prognostic or predictive value. We did found that
subjects with hilar/mediastinal lymphadenopathy more often
showed multiplicity of PFNs in the lung, which might repre-
sent their reactive nature.
The strength of this study is that it evaluates PFNs
outside a lung cancer-screening setting, confirming in a
daily-routine, heterogeneous population that they do not
represent lung cancer. This includes patients with incident
lung cancers as well as non-cancer subjects with or with-
out prior extra-pulmonary malignancies.
Our study has several limitations. First, it had a retro-
spective study design with related heterogeneity of imag-
ing protocols. For the sole purpose of PFN identification,
however, we feel this is not a major factor. Nearly all in-
cluded examinations were thin-slice images that allow
good evaluation of small nodules in different reconstruc-
tion planes. Heterogeneity of imaging protocols may have
had some influence on nodule segmentation. Given that
PFNs were often small, limited segmentation differences
may account for some of the observed growth. Second,
results might have been influenced by the interpretation
of lung nodule type in this single-observer study. We have
given a clear definition of what was regarded a PFN versus
a non-PFN lesion; however, some variation in interpreta-
tion is to be expected on a nodule-to-nodule basis. As far as
we know, interobserver variability in PFN determination is
currently not known, but it is well known from other lung
nodule interpretation tasks that observer variation exists.
Although some misclassification might thus be present in
our study, separation between typical or atypical PFNs was
not of importance in this study, and none of our PFNs
turned out to be malignant. Third, our study had to rely
on the National Cancer Registry for outcome data. This is
less optimal than a study with several consecutive
(screening) rounds and prospective follow-up. Due to this
design, vital status was available for cases but not for con-
trols, which overestimates their follow-up period.
Nevertheless, the National Cancer Registry centrally regis-
ters all cancer cases in The Netherlands, irrespective of
hospital. So, although control subjects may have died ear-
lier than the end of our study period, we do know they did
not develop lung cancer. Last, we do not have pathological
evidence of the benign nature of all PFNs. Theoretically, a
growing PFN could be based on a metastasis; however,
evidence on that is anecdotal in the literature [16–18] and
none grew continuously.
In conclusion, our study evaluates PFN presence and be-
haviour in a daily-routine, heterogeneous population. Results
show that PFNs do not represent lung cancer, confirming prior
results from lung cancer-screening studies. Given that small
non-calcified nodules are a frequently encountered entity in
every practice, and that a substantial percentage of these nod-
ules represents a PFN, a leave-alone strategy substantially
influences nodule management practice and reduces the num-
ber of follow-up CT examinations significantly.
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